ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025.Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024 Generated net income of $25.7 million or $0.70 per fully diluted share in ...

Expects to Achieve Projected Annual Revenue of $90 MillionBEIJING, May 8, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or "the Company"), a Nevada-based digital technology company specializing in acoustics high-tech and 5G+AI multimodal digital innovations, today pre-announced its revenue for the third quarter of fiscal year 2025, ended March 31, 2025, which is expected to be approximately $51.9 million, representing an increase of approximately 164.6%, as compared to approximately $19.6 mill ...

Award recognizes Novasight Hybrid™ System’s significant advance in intracoronary imaging technologyTORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its Novasight Hybrid™ System (“Novasight”) has been named "Product Innovation of the Year" at the 2025 Min ...

Core Insights - Pasithea Therapeutics Corp. announced positive interim pharmacodynamic data from its Phase 1 trial of PAS-004, a macrocyclic MEK inhibitor targeting neurofibromatosis type 1 and other MAPK pathway-driven cancers [1][5] - The trial demonstrated up to 91% inhibition of pERK, confirming substantial target engagement and a favorable pharmacological profile [1][3] - One patient with stage 4 KRAS G12R mutated pancreatic cancer showed a tumor volume reduction of -9.8% over 5 months of treatment with PAS-004 [1][4] Pharmacodynamic Data - Inhibition of ERK phosphorylation (pERK) is a recognized biomarker for assessing MEK inhibitor activity, with measurements taken from patients at baseline and day 22 [2] - The results indicated robust pERK inhibition, with reductions of up to 91% at the 8mg dose level, aligning with previous PK/PD models [3] Clinical Observations - Preliminary clinical observations showed several patients achieving stable disease and tumor shrinkage while on PAS-004 treatment [4] - The ongoing Phase 1 trial is a multi-center, open-label, dose escalation study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with MAPK pathway-driven advanced solid tumors [5] Company Overview - Pasithea Therapeutics is focused on developing innovative treatments for central nervous system disorders, RASopathies, and MAPK pathway-driven tumors [6]

Recognized in both pre-and post-approval pharmacovigilance operationsDURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a “Leader” for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea’s top position was recognized in both pre-and post-approval PV operations in Everest Group’s proprietary framework, which assess ...

More than half say genetic testing for mental health medications could reduce concernsSALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, I ...

Core Insights - New pharmacogenomic data on the impact of the UNC13A genotype on treatment response in ALS patients treated with NurOwn® will be presented at the ISCT 2025 Annual Meeting [1][2] - The findings are significant as they may help predict treatment responses based on genetic factors, advancing personalized medicine for ALS [2][3] Company Overview - BrainStorm Cell Therapeutics Inc. is a leading developer of autologous adult stem cell therapies for neurodegenerative diseases, with its proprietary NurOwn® platform utilizing mesenchymal stem cells to produce neurotrophic factor-secreting cells [4][5] - NurOwn® has received Orphan Drug designation from both the FDA and EMA, and a Phase 3 trial in ALS has been completed, with a confirmatory Phase 3b trial set to launch under a Special Protocol Assessment agreement with the FDA [5][6] Clinical Development - The upcoming Phase 3b trial aims to build on existing clinical data and demonstrate NurOwn's potential in early ALS, with positive communication ongoing with the FDA [3][5] - The recent findings provide insights into treatment effects in patient subpopulations and represent a first-of-its-kind pharmacogenomic analysis in ALS, focusing on how genetic differences affect therapy response [3][6] Presentation Details - The oral presentation titled "Debamestrocel Effect on Clinical and Biomarker Endpoints by UNC13A Genotype in Phase 3 ALS Trial" will take place on May 8, 2025, at the ISCT meeting in New Orleans [3]

Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug. The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis. Data also show a significant decrease in ANP (Atrial Natriuretic Peptide), a clinically validated marker for heart failure. T ...

RA'ANANA, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the successful completion of the first human treatment using its U.S. Food and Drug Administration-cleared INSPIRA™ ART100 system in a critical life-support procedure. The procedure was successfully performed by expert physicians at Westchester Medical Center in New York State, marking ...

BrightSpring Health Services (BTSG) Q4 2024 Earnings Call March 06, 2025 08:30 AM ET Company Participants David Deuchler - Managing DirectorJon Rousseau - Chairman, President & CEOJennifer Phipps - EVP & CFOA.J. Rice - Managing DirectorWhit Mayo - Senior Managing DirectorMatthew Gillmor - Director & Senior Research Aanalyst Conference Call Participants Brian Tanquilut - Equity Research Analyst - Healthcare ServicesDavid Larsen - Analyst, Managing DirectorJoanna Gajuk - Equity Research AnalystErin Wright - S ...